2nd ADC Target Selection Summit

Kongressthemen
With no room for error in the highly competitive ADC market and no going back after you have selected your target, it is vital that drug developers optimally triangulate the linker-payload, target and indication to develop an ADC that can have the biggest impact on patients.

Recent exciting developments in linker-payload technologies and clinical efficacy in low-expressed tumors have propelled this conversation to the forefront of mind.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Brochure: https://go.evvnt.com/1261856-3?pid=4832

Speakers: Jagath Reddy Junutula, President, Chief Executive Officer and Co-Founder, Aarvik Therapeutics, Yu Shen, Director, Oncology Discovery, AbbVie, and more.

https://go.evvnt.com/1261856-2?pid=4832

Frau Aarti Diwan